[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rejection-heart-transplant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rejection-heart-transplant":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100644791","extracellular-vesicles-for-rejection-monitoring-in-cardiac-transplantation-100644791",false,"NCT07673536","Extracellular Vesicles for Rejection Monitoring in Cardiac Transplantation","ExoRejeCT","Inclusion Criteria:\n\n* Subject is either on the heart transplant waiting list or is still hospitalised following HTx surgery.\n* Age of subject is ≥ 18 years.\n* Subject is female or male.\n* Capacity to consent.\n* Signed written informed consent.\n* For female subjects:\n\n  1. Confirmed post-menopausal state, defined as amenorrhea for at least 12 months, or\n  2. If being of childbearing potential: Negative highly sensitive urine or serum pregnancy test before inclusion.\n\nExclusion Criteria:\n\n* Concurrent multiple solid organ or tissue transplants.\n* Prior history of any organ or cellular transplantation.\n* Subject suffers from an addiction or from a disease that prevents the subject from recognising nature, scope, and consequences of the study.\n* Subject shows an inability to comply with all the study procedures and follow-up visits.\n* Subject is legally detained in an official institution.\n* Subjects who are unwilling to consent to saving and propagation of pseudonymised medical data for study reasons.\n* Subject is financially dependent on the investigators or the study site.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","OBSERVATIONAL","This study will analyze extracellular vesicle (EV)-derived protein profiles in heart transplantated patients during the first 15 months post-transplantation to investigate, if there are distinct EV-derived proteins or protein patterns that allow early and reliable diagnosis of acute cardiac allograft rejection. Additionally, it will explore temporal changes in the EV-derived protein profile during the early postoperative period irrespective of acute allograft rejection, and will investigate, if there are correlations between EV protein markers and imaging findings.",[24],"Rejection Heart Transplant","RECRUITING","2026-06-30",{"date":28,"type":29},"2026-07-01","ACTUAL",{"date":31,"type":29},"2026-06-18",{"date":33,"type":20},"2028-11-30",{"name":35,"class":36},"Laurenz Kopp Fernandes","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":47,"conditions":48,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":60},"100575598","cardiac-imaging-and-biomarkers-in-the-diagnosis-of-antibody-mediated-rejection-in-heart-transplantation-100575598","NCT06774365","CARdiac Imaging and BIomarkers in the Diagnosis of Antibody Mediated Rejection in Heart Transplantation","CARIBIAM","Inclusion Criteria:\n\n* Age \\> 18 years\n\n  * Post heart transplantation follow-up between 1 and 15 y\n  * Ambulatory clinical stable\n  * Left ventricular ejection fraction (LVEF) \\> 40% (as assessed by complete cardiac ultrasound within 3 months before the enrolment)\n\nExclusion Criteria:\n\n* Unplanned hospitalization for cardiovascular causes in the previous three months\n\n  * Biopsy-proven cellular (2R or greater) or AMR (pAMR\\> 1 ) in the previous 3 months\n  * Any contraindication to CMR\n  * Known pregnancy",{"count":46,"type":20},683,"The goal of this observational study is to systematically assess the presence and distribution of CMR-defined inflammation and fibrosis in clinically stable HT recipients with DSA detected during active screening for AMR surveillance. The main outcome is to study the prevalence of fibrosis, edema and of altered T1 mapping values in patients with DSA and the prevalence of patients with DSA among all the enrolled patients",[49,24,50],"Heart Transplantation","HLA Antigens","2026-05-20",{"date":53,"type":29},"2026-05-22",{"date":55,"type":29},"2024-11-07",{"date":57,"type":20},"2029-12",{"name":59,"class":36},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",4]